Terms: = Cervical cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Diagnosis
23 results:
1. Advanced detection of cervical cancer biomarkers using engineered filamentous phage nanofibers.
Zhou X; Wang Y; Bao M; Chu Y; Liu R; Chen Q; Lin Y
Appl Microbiol Biotechnol; 2024 Feb; 108(1):221. PubMed ID: 38372795
[TBL] [Abstract] [Full Text] [Related]
2. cervical lymphoepithelioma-like carcinoma with deficient mismatch repair and loss of SMARCA4/BRG1: a case report and five related cases.
Miyama Y; Kato T; Sato M; Yabuno A; Hasegawa K; Yasuda M
Diagn Pathol; 2024 Jan; 19(1):6. PubMed ID: 38178127
[TBL] [Abstract] [Full Text] [Related]
3. Identification of a prognostic model based on immune and hypoxia-related gene expressions in cervical cancer.
Wang L; Wang C; He Y; Jin M; Lin L; Jiao X; Hu X; Wang Y
J Obstet Gynaecol; 2023 Dec; 43(2):2277242. PubMed ID: 37938121
[TBL] [Abstract] [Full Text] [Related]
4. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Monk BJ; Tewari KS; Dubot C; Caceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüş M; Hurtado de Mendoza MO; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Martin Nguyen A; Monberg MJ; Colombo N; Lorusso D
Lancet Oncol; 2023 Apr; 24(4):392-402. PubMed ID: 36878237
[TBL] [Abstract] [Full Text] [Related]
5. Application of Immune Checkpoint Inhibitors in Gynecological cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
Lee SM; Lee S; Cho HW; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674491
[TBL] [Abstract] [Full Text] [Related]
6. O-Glycosylating Enzyme GALNT2 Predicts Worse Prognosis in cervical cancer.
Zhou L; Wu H; Bai X; Min S; Zhang J; Li C
Pathol Oncol Res; 2022; 28():1610554. PubMed ID: 36110252
[TBL] [Abstract] [Full Text] [Related]
7. Predictive values of PD‑L1 expression for survival outcomes in patients with cervical cancer: a systematic review and meta-analysis.
Hu T; Wan X; Wu H; Cheng X; Xu S
Ginekol Pol; 2022; 93(10):767-774. PubMed ID: 35984342
[TBL] [Abstract] [Full Text] [Related]
8. [Clinicopathological features of mixed cervical carcinoma with adenoid cystic pattern].
Li LL; Cui YY; Gao PY; Xia L; Liu GZ; Liu H
Zhonghua Bing Li Xue Za Zhi; 2022 Jul; 51(7):615-620. PubMed ID: 35785831
[No Abstract] [Full Text] [Related]
9. Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients.
Omenai SA; Ajani MA; Okolo CA
PLoS One; 2022; 17(2):e0263615. PubMed ID: 35139126
[TBL] [Abstract] [Full Text] [Related]
10. pd-l1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
Wang R; Zhang Y; Shan F
Int Immunopharmacol; 2022 Feb; 103():108484. PubMed ID: 34954558
[TBL] [Abstract] [Full Text] [Related]
11. Clinical and pathological analysis of companion diagnostic testing of microsatellite instability-high for pembrolizumab in gynaecologic malignancy.
Takeda T; Tsuji K; Kobayashi Y; Banno K; Aoki D
Jpn J Clin Oncol; 2022 Feb; 52(2):128-133. PubMed ID: 34750611
[TBL] [Abstract] [Full Text] [Related]
12. Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors.
Buza N
Semin Diagn Pathol; 2022 Jan; 39(1):58-77. PubMed ID: 34750021
[TBL] [Abstract] [Full Text] [Related]
13. Expression of the HOXA gene family and its relationship to prognosis and immune infiltrates in cervical cancer.
Ge F; Tie W; Zhang J; Zhu Y; Fan Y
J Clin Lab Anal; 2021 Nov; 35(11):e24015. PubMed ID: 34606634
[TBL] [Abstract] [Full Text] [Related]
14. Focused Neck Ultrasound and Lymph Node Sampling by Respiratory Physicians in Suspected Lung cancer.
Hassan M; Nicholson T; Taylor L; McDill H; Hadden R; Syred K; Riordan R; Howell T; Corcoran JP; Daneshvar C
Respiration; 2022; 101(1):57-62. PubMed ID: 34515221
[TBL] [Abstract] [Full Text] [Related]
15. Mixed and nonvaccine high risk HPV types are associated with higher mortality in Black women with cervical cancer.
Mendoza RP; Haidary T; Gabutan E; Zhou YY; Bukhari Z; Connelly C; Lee WC; Lee YC; Wadgaonkar R; Agrawal R; Haseeb MA; Gupta R
Sci Rep; 2021 Jul; 11(1):14064. PubMed ID: 34234252
[TBL] [Abstract] [Full Text] [Related]
16. [The Clinical Significance of HPV L1/pd-l1 Tests Combined with Colposcopy for cervical Precancerous Lesions and cervical cancer].
Luo GP; Zeng X; Cao HY; Tang D; Xi MR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 May; 52(3):516-522. PubMed ID: 34018374
[TBL] [Abstract] [Full Text] [Related]
17. Diagnostic Value of Vaginal Microecology, Serum miR-18a, and pd-l1 for Identifying HPV-Positive cervical cancer.
Zhang Y; Qiu S; Guo Y; Zhang J; Wu X; Hong G
Technol Cancer Res Treat; 2021; 20():1533033821995281. PubMed ID: 33632085
[TBL] [Abstract] [Full Text] [Related]
18. MiR-374b increases the CIK expression and mediates biological function changes in cervical cancer cells by targeting the PD-1/pd-l1 signaling pathway.
Wang C; Kuang L; Han L
J Reprod Immunol; 2021 Feb; 143():103265. PubMed ID: 33360511
[TBL] [Abstract] [Full Text] [Related]
19. Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer.
Zhang Y; Yu M; Jing Y; Cheng J; Zhang C; Cheng L; Lu H; Cai MC; Wu J; Wang W; Lou W; Qiu L; Tan L; Lu H; Yin X; Zhuang G; Di W
Br J Cancer; 2021 Jan; 124(2):414-424. PubMed ID: 33087896
[TBL] [Abstract] [Full Text] [Related]
20. Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors.
de Andrea CE; Perez-Gracia JL; Castanon E; Ponz-Sarvise M; Echeveste JI; Melero I; Sanmamed MF; Rodriguez-Ruiz ME
Oncoimmunology; 2020 May; 9(1):1760676. PubMed ID: 32934876
[TBL] [Abstract] [Full Text] [Related]
[Next]
